Tumour Targeting with Rationally Modified Cell-Penetrating Peptides

[1]  Ü. Langel,et al.  Cell-Penetrating Peptides in Cancer Targeting , 2011 .

[2]  F. Kratz,et al.  Drug delivery in oncology : from basic research to cancer therapy , 2011 .

[3]  L. Ye,et al.  Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. , 2011, Oncology reports.

[4]  P. Laakkonen,et al.  Homing peptides as targeted delivery vehicles. , 2010, Integrative biology : quantitative biosciences from nano to macro.

[5]  Ű. Langel,et al.  Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. , 2010, Biochimica et biophysica acta.

[6]  A. Karlström,et al.  Design of protecting groups for the beta-carboxylic group of aspartic acid that minimize base-catalyzed aspartimide formation. , 2009, International journal of peptide and protein research.

[7]  André Pèlegrin,et al.  Cell-penetrating and cell-targeting peptides in drug delivery. , 2008, Biochimica et biophysica acta.

[8]  Ű. Langel,et al.  Predicting cell-penetrating peptides. , 2008, Advanced drug delivery reviews.

[9]  R. Castelein,et al.  Increased MMP‐2 activity during intervertebral disc degeneration is correlated to MMP‐14 levels , 2008, The Journal of pathology.

[10]  P. Guldberg,et al.  Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B‐cell lymphoma , 2007, European journal of haematology.

[11]  M. Pooga,et al.  Studying the uptake of cell-penetrating peptides , 2006, Nature Protocols.

[12]  H. Spring,et al.  Delivery of substances and their target-specific topical activation. , 2006, Biochimica et biophysica acta.

[13]  B. Franc,et al.  Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation. , 2006, Bioconjugate chemistry.

[14]  Ű. Langel,et al.  Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. , 2006, Biochemical pharmacology.

[15]  Roger Y Tsien,et al.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Kamps,et al.  The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. , 2004, Critical reviews in oncology/hematology.

[17]  B. Bauvois.  Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? , 2004, Oncogene.

[18]  H. Mori,et al.  Membrane-type 1 matrix metalloproteinase and cell migration. , 2003, Biochemical Society symposium.

[19]  O. Paciello,et al.  Expression of matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas. , 2002, Journal of comparative pathology.

[20]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[21]  E. Schönherr,et al.  Matrix metalloproteinase expression by endothelial cells in collagen lattices changes during co‐culture with fibroblasts and upon induction of decorin expression , 2001, Journal of cellular physiology.

[22]  T. Krieg,et al.  Tissue Inhibitor of Matrix Metalloproteinase-2 Regulates Matrix Metalloproteinase-2 Activation by Modulation of Membrane-type 1 Matrix Metalloproteinase Activity in High and Low Invasive Melanoma Cell Lines* , 1999, The Journal of Biological Chemistry.

[23]  Y. Okada,et al.  Activation of the precursor of gelatinase A/72 kda type IV collagenase/MMP‐2 in lung carcinomas correlates with the expression of membrane‐type matrix metalloproteinase (MT‐MMP) and with lymph node metastasis , 1995, International journal of cancer.

[24]  G. Fields,et al.  Sequence dependence of aspartimide formation during 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis , 1995, Letters in Peptide Science.

[25]  Ű. Langel,et al.  Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. , 2011, Therapeutic delivery.

[26]  Ülo Langel,et al.  Design of a Tumor-Homing Cell-Penetrating Peptide , 2008 .